ALANA HARRIS: Open Payments
NPI 1891026266 · CATONSVILLE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,712 in 146 payments from 21 companies in 2025. Trend: 2023 $2,430 · 2024 $3,225 · 2025 $4,712
Food & beverage: $4,712
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 25 | $1,375 |
| Gilead Sciences, Inc. | 25 | $832 |
| Janssen Biotech, Inc. | 16 | $487 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $482 |
| GENZYME CORPORATION | 9 | $399 |
| ABBVIE INC. | 8 | $150 |
| Ardelyx, Inc. | 10 | $144 |
| Novo Nordisk Inc | 2 | $136 |
| Aimmune Therapeutics, Inc. | 5 | $128 |
| PFIZER INC. | 6 | $105 |
Products named: REZDIFFRA, TREMFYA, DUPIXENT, ENTYVIO, Livdelzi, IBSRELA, Wegovy, VOWST.
Industry payments across MD — which companies pay providers there.
